FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
The FDA has accepted the supplemental BLA for OCREVUS ZUNOVO, which includes ocrelizumab and hyaluronidase.
Therapeutic Area
Therapeutic area intelligence for MS with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.